Trial Profile
An Open Label, Multicenter, Dose Finding, Single Arm, Phase 1 Study of Fusilev® (Levoleucovorin) to Prevent or Reduce Mucositis in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer Receiving Folotyn® (Pralatrexate)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 07 Oct 2022
Price :
$35
*
At a glance
- Drugs Levofolinic acid (Primary) ; Pralatrexate
- Indications Mucositis
- Focus Therapeutic Use
- Sponsors Spectrum Pharmaceuticals
- 30 Apr 2015 New trial record